Pretraga

Rezultati

Agreement on risk assessment and chemotherapy recommendations among breast cancer specialists: A survey within the MINDACT cohort [2023]

Cardozo, Josephine MN; Veira, Sherylene E.; Hassou, Laila Ait; Uwiana, Aime´ Lambert; Božović-Spasojević, Ivana; Bogaerts, Jan; Cardoso, Fatima

Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial (vol 83, 104547, 2025) [2025]

Demeestere, Isabelle; ...; Susnjar, Snezana V ; ...; (broj, koautora 36)

PR118 SIGNIFICANCE OF GENE AMPLIFICATIONS ON RELAPSE-FREE SURVIVAL (RFS) AND OVERALL SURVIVAL (OS) IN METASTATIC BREAST CANCER [2013]

Todorović-Raković, Nataša ; Neskovic-Konstantinovic, Zora ; Nikolić Vukosavljević, Dragica

A borderline phyllodes breast tumor clinicaly presented as giant exulcerated suspicious malignant tumor [2019]

Spasic, Marko B ; Ninkovic, Srdjan M; Nedovic, Jasmina R; Mitrovic, Slobodanka Lj; Markovic, Ivan Z; Milosevic, Bojan Z ; Inic, Zorka M; Goran, Merima; Kocic, Milan; Radovanovic, Dragce M

P234 Influence of younger age to disease outcome in patients with breast cancer after adjuvant systemic chemotherapy and adjuvant hormone therapy [2017]

Milovic, Marijana M

Do we follow the guidelines: first systemic therapy choice for metastatic hormone receptor-positive breast cancer patients treated at the Institute for Oncology and Radiology in Serbia [2019]

Serovic, Kristina; Jokic, Vladimir; Bozovic-Spasojevic, Ivana M

Hormon Positive Breast Cancer with Early Relapse [2023]

Jovisevic, Marija; Brdar-Zelen, Teodora; Prica, Anja

Impact of body mass index (BMI) on pathological response after neoadjuvant therapy (NAT) in patients with hormone receptor (HR) and HER2 positive early breast cancer (eBC) - single center experience [2025]

Djurmez, O; Calamac, M; Dimitrijevic, M; Minic, I; Oblakovic-Babic, J; Serovic, K; Stanic, N; Mihajlovic, S; Gavrilovic, D; Bozovic-Spasojevic, I

Can body mass index (BMI) impact the treatment outcomes in postmenopausal women with hormone receptor positive (HR+) HER-2 negative early breast cancer (BC)? [2025]

Calamac, M; Djurmez, O; Dimitrijevic, M; Gavrilovic, D; Minic, I; Bozovic-Spasojevic, I

Long-term trastuzumab treatment in HER2 positive metastatic breast cancer [2021]

Calamac, Marina; Minic, Ivana Z; Tomasevic, Zoran M; Oblakovic-Babic, Jelena S; Serovic, Kristina; Djurmez, Ognjen; Dimitrijevic, M; Bozovic-Spasojevic, Ivana M